Literature DB >> 17074440

Slow isomerization step in the interaction between mouse dopamine transporter and dopamine re-uptake inhibitor N-(3-iodoprop-2E-enyl)-2beta-carbo-[3H]methoxy-3beta-(4'-methylphenyl)nortropane.

Vladimir Stepanov1, Jaak Järv.   

Abstract

The kinetics of the association and dissociation of the tritium-labeled selective and potent dopamine transporter inhibitor N-(3-iodoprop-2E-enyl)-2beta-carbo-[3H]methoxy-3beta-(4'-methylphenyl)nortropane ([3H]PE2I) with the transporter of mouse striatal membranes was studied. The analysis revealed that the specific binding of [3H]PE2I occurs within a homogeneous population of binding sites in these membranes. The relatively slow binding process was characterized by the pseudo-first-order rate constant kobs. The plot of these rate constants versus free radioligand concentration was hyperbolic, demonstrating that at least two kinetically distinguishable steps can be identified in the interaction of dopamine transporter with this inhibitor. The fast and reversible binding step, characterized by dissociation constant KA = 51 +/- 23 nM, is followed by a slow but also reversible isomerization step of the complex, characterized by the isomerization rate constant ki = (7 +/- 2)10(-2) s(-1) and by the rate constant k(-i) = (3.9 +/- 0.5)10(-3) s(-1) for the reverse process. This isomerization step increases the apparent affinity of the ligand and probably consists of a conformational transition of the transporter protein, induced by the inhibitor molecule.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074440     DOI: 10.1016/j.neulet.2006.10.007

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Thermal Stability of Dopamine Transporters.

Authors:  Siim Kukk; Vladimir Stepanov; Jaak Järv
Journal:  J Membr Biol       Date:  2015-03-27       Impact factor: 1.843

Review 2.  PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.

Authors:  Patrick Emond; Denis Guilloteau; Sylvie Chalon
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.